Not applicableStudy completedNCT04175262
What this trial is testing
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Who this might be right for
Metastatic Renal Cell Carcinoma (mRCC)
Pfizer 102